Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MVA-BN Filo vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-BN-Filo

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Janssen Pharmaceutical

            Deal Size: $13.9 million Upfront Cash: Undisclosed

            Deal Type: Agreement June 18, 2020


            Bavarian Nordic will manufacture and deliver bulk drug substance of its MVA-BN Filo vaccine, which Janssen has licensed as part of its Ebola vaccine regimen.